EU antitrust - Article 102 TFEU

Dominance

Article 102 TFEU prohibits undertakings that (individually or collectively) hold a dominant position within the EU or a substantial part of it from abusing their dominance (without objective justification) insofar as it may affect trade between Member States. This provision is mirrored in the national competition laws of EU Member States and which can apply even where an effect on inter-state trade is not established.

The distinction between abusive and legitimate (permissible) conduct by a dominant undertaking may be hard to discern—for example, a price reduction resulting from production efficiencies/economies as opposed to a ‘predatory’ price cut. Dominant undertakings are permitted (and indeed expected) to compete aggressively on a given market but such behaviour should reflect competition ‘on the merits’.

The application of Article 102 TFEU has three constituent elements:

  1. establishing ‘dominance’

  2. confirming prima facie restrictive unilateral conduct, and

  3. assessing whether there is ‘objective justification’ for any such conduct—if not (and only then) can the conduct in question legally be construed as an ‘abuse’

For further information, see Practice Notes: Article 102 TFEU—the prohibition on abuse of dominance and Dominant

To view the latest version of this document and thousands of others like it, sign-in with LexisNexis or register for a free trial.

Powered by Lexis+®
Latest EU Law News

MedTech Europe leads industry call for EU to provide medical device regulatory relief by early 2026

MedTech Europe, together with 35 national associations, has urged the European Commission to take swift action on regulatory challenges affecting the medical device and diagnostic sectors. While EU officials are already collecting evidence to support future reforms of the medical device and in vitro diagnostic regulations, which are meant to simplify and improve efficiency, the signatories of the open letter argue that immediate relief is also essential. They call for a combination of short-term measures alongside longer-term legislative reforms. In particular, the letter asks for an implementing act to standardize the work of notified bodies, pilot projects for regulatory pathways covering orphan, pediatric, and breakthrough devices, and a targeted delay of re-certification requirements for certain products. According to MedTech Europe, harmonizing rules for notified bodies would help reduce duplication, speed up assessments, and ease the overall regulatory burden. The proposed postponement of re-certification deadlines is seen as necessary to avoid bottlenecks that could disrupt the supply of devices ahead of 2028. Looking further ahead, the associations want amendments to both MDR and IVDR that reflect the specific needs of each sector, alongside the creation of a single governance structure to oversee notified bodies and the CE-marking system, which they consider vital to the future of European medical technology regulation.

View EU Law by content type :

Popular documents